| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2015 |
Liu S, Lee JJ. An overview of the design and conduct of the BATTLE trials. Chinese Clinical Oncology. 4: 33. PMID 26408300 DOI: 10.3978/j.issn.2304-3865.2015.06.07 |
0.237 |
|
| 2015 |
Zang Y, Liu S, Yuan Y. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers Journal of the Royal Statistical Society. Series C: Applied Statistics. 64: 635-650. DOI: 10.1111/Rssc.12092 |
0.222 |
|
| 2013 |
Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 658-61. PMID 23584298 DOI: 10.1097/JTO.0b013e31828d08ae |
0.221 |
|
| 2012 |
Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1645-52. PMID 23059780 DOI: 10.1097/JTO.0b013e31826910ff |
0.218 |
|
| 2016 |
Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences. 8: 99-128. PMID 27617040 DOI: 10.1007/s12561-014-9124-2 |
0.218 |
|
| 2011 |
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery. 1: 44-53. PMID 22586319 DOI: 10.1158/2159-8274.CD-10-0010 |
0.212 |
|
| 2018 |
Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association. 113: 1016-1027. PMID 31741544 DOI: 10.1080/01621459.2017.1383260 |
0.211 |
|
| 2009 |
Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 115: 1091-9. PMID 19165805 DOI: 10.1002/Cncr.24018 |
0.21 |
|
| 2020 |
Halperin DM, Liu S, Dasari A, Fogelman DR, Bhosale P, Mahvash A, Dervin S, Estrella J, Cortazar P, Maru DM, Mckenna EF, Wistuba II, Schulze K, Futreal PA, Darbonne WC, et al. A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). Journal of Clinical Oncology. 38: 619-619. DOI: 10.1200/jco.2020.38.4_suppl.619 |
0.207 |
|
| 2014 |
Cai C, Liu S, Yuan Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 33: 4017-28. PMID 24817556 DOI: 10.1002/Sim.6200 |
0.207 |
|
| 2022 |
Park Y, Liu S. A randomized group sequential enrichment design for immunotherapy and targeted therapy. Contemporary Clinical Trials. 116: 106742. PMID 35405335 DOI: 10.1016/j.cct.2022.106742 |
0.206 |
|
| 2022 |
Douglas JE, Liu S, Ma J, Wolff RA, Pant S, Maitra A, Tamm EP, Bhosale P, Katz MHG, Varadhachary GR, Koay EJ. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Bmc Cancer. 22: 14. PMID 34980020 DOI: 10.1186/s12885-021-09095-7 |
0.206 |
|
| 2015 |
Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 507-523. DOI: 10.1111/Rssc.12089 |
0.205 |
|
| 2021 |
Park Y, Liu S, Thall P, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics. PMID 33438761 DOI: 10.1111/biom.13421 |
0.201 |
|
| 2013 |
Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6967-75. PMID 24166906 DOI: 10.1158/1078-0432.CCR-12-1818 |
0.195 |
|
| 2014 |
Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Journal of the American Statistical Association. 109: 525-536. PMID 25382884 DOI: 10.1080/01621459.2014.881740 |
0.195 |
|
| 2019 |
Guo B, Liu S. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Biometrical Journal. Biometrische Zeitschrift. PMID 31402481 DOI: 10.1002/bimj.201900022 |
0.195 |
|
| 2021 |
Park Y, Yuan Y, Ning J, Liu S, Feng Z. Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in Medicine. PMID 33540472 DOI: 10.1002/sim.8890 |
0.189 |
|
| 2016 |
Zang Y, Liu S, Yuan Y. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics (Oxford, England). PMID 26951724 DOI: 10.1093/Biostatistics/Kxw006 |
0.188 |
|
| 2022 |
Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, et al. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. Jama Oncology. PMID 35389428 DOI: 10.1001/jamaoncol.2022.0212 |
0.188 |
|
| 2021 |
Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, et al. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Investigational New Drugs. PMID 34559346 DOI: 10.1007/s10637-021-01184-5 |
0.184 |
|
| 2011 |
Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prevention Research (Philadelphia, Pa.). 4: 1580-9. PMID 21881030 DOI: 10.1158/1940-6207.CAPR-11-0036 |
0.184 |
|
| 2010 |
Herbst RS, Blumenschein GR, Kim ES, Lee J, Tsao AS, Alden CM, Liu S, Stewart DJ, Wistuba II, Hong WK. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Journal of Clinical Oncology. 28: 7609-7609. DOI: 10.1200/JCO.2010.28.15_SUPPL.7609 |
0.183 |
|
| 2008 |
Wheler JJ, Tsimberidou AM, Hong DS, Jackson TL, Polk DY, Pilat S, Liu S, Feng L, Kurzrock R. Survival of patients in a phase I clinic: The M. D. Anderson Cancer Center experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11066. PMID 27947723 DOI: 10.1200/Jco.2008.26.15_Suppl.11066 |
0.182 |
|
| 2011 |
Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Statistics in Medicine. 30: 1218-29. PMID 21432894 DOI: 10.1002/Sim.4218 |
0.18 |
|
| 2010 |
Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clinical Breast Cancer. 10: 46-51. PMID 20133258 DOI: 10.1200/Jco.2009.27.15_Suppl.1054 |
0.177 |
|
| 2009 |
William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. American Journal of Clinical Oncology. 32: 15-9. PMID 19194117 DOI: 10.1097/COC.0b013e318178e513 |
0.177 |
|
| 2013 |
Liu S, Yin G, Yuan Y. BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. The Annals of Applied Statistics. 7: 1837-2457. PMID 24707327 DOI: 10.1214/13-Aoas661 |
0.177 |
|
| 2011 |
Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 2104-11. PMID 21892101 DOI: 10.1097/JTO.0b013e31822e7256 |
0.175 |
|
| 2020 |
Park Y, Liu S. On the coherence of model-based dose-finding designs for drug combination trials. Plos One. 15: e0242561. PMID 33253260 DOI: 10.1371/journal.pone.0242561 |
0.174 |
|
| 2015 |
Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine. 34: 1681-94. PMID 25626429 DOI: 10.1002/Sim.6442 |
0.172 |
|
| 2013 |
Liu S, Ning J. A bayesian dose-finding design for drug combination trials with delayed toxicities Bayesian Analysis. 8: 703-722. DOI: 10.1214/13-BA839 |
0.169 |
|
| 2012 |
Liu S. Improving Financial Stability: Can European Union Member States Learn From China's Experience in Enhancing Commercial Banks' Social Responsibilities? European Law Journal. 18: 108-121. DOI: 10.1111/J.1468-0386.2011.00588.X |
0.167 |
|
| 2023 |
Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Bravo PL, Qiao W, Liu S, Yao L, Lin SH, Reuben JM. Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer. Translational Lung Cancer Research. 12: 109-126. PMID 36762061 DOI: 10.21037/tlcr-22-314 |
0.166 |
|
| 2013 |
Liu S, Ning J. A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Analysis. 8: 703-722. PMID 27924182 DOI: 10.1214/13-Ba839 |
0.166 |
|
| 2022 |
Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang C. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND. International Journal of Radiation Oncology, Biology, Physics. PMID 35691448 DOI: 10.1016/j.ijrobp.2022.05.023 |
0.163 |
|
| 2018 |
Guo B, Park Y, Liu S. A utility‐based Bayesian phase I–II design for immunotherapy trials with progression‐free survival end point Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 411-425. DOI: 10.1111/RSSC.12288 |
0.16 |
|
| 2020 |
Raghav KPS, Overman MJ, Liu S, Willett A, Royal RE, Malpica A, Scally C, Wistuba II, Futreal A, Mahvash A, Yun C, Dervin S, Mckenna EF, Schulze K, Hwu P, et al. A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. Journal of Clinical Oncology. 38: 9013-9013. DOI: 10.1200/jco.2020.38.15_suppl.9013 |
0.155 |
|
| 2020 |
Pezzi TA, Fang P, Gjyshi O, Feng L, Liu S, Komaki R, Lin SH. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. Jama Network Open. 3: e201929. PMID 32236532 DOI: 10.1001/jamanetworkopen.2020.1929 |
0.153 |
|
| 2015 |
Liu S, Johnson VE. A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics (Oxford, England). PMID 26486139 DOI: 10.1093/Biostatistics/Kxv040 |
0.152 |
|
| 2020 |
Cohen EN, Jayachandran G, Gao H, Qiao W, Liu S, He J, Qiao Y, Yao L, Lin SH, Reuben JM. Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients. Translational Lung Cancer Research. 9: 1974-1985. PMID 33209617 DOI: 10.21037/tlcr-20-841 |
0.152 |
|
| 2024 |
Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials (London, England). 17407745231207085. PMID 38243399 DOI: 10.1177/17407745231207085 |
0.147 |
|
| 2008 |
Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clinical Trials (London, England). 5: 181-93. PMID 18559407 DOI: 10.1177/1740774508091815 |
0.147 |
|
| 2012 |
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. Journal of the National Cancer Institute. 104: 228-39. PMID 22247021 DOI: 10.1093/jnci/djr523 |
0.144 |
|
| 2009 |
Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Annals of Surgical Oncology. 16: 2181-7. PMID 19475451 DOI: 10.1245/s10434-009-0523-4 |
0.144 |
|
| 2021 |
Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. Jama Network Open. 4: e2037563. PMID 33595664 DOI: 10.1001/jamanetworkopen.2020.37563 |
0.143 |
|
| 2013 |
Liu S, Cai C, Ning J. Up-and-down designs for phase I clinical trials. Contemporary Clinical Trials. 36: 218-27. PMID 23856381 DOI: 10.1016/j.cct.2013.07.002 |
0.141 |
|
| 2023 |
Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. Jama Oncology. PMID 37022702 DOI: 10.1001/jamaoncol.2023.0161 |
0.14 |
|
| 2008 |
Johnson ED, Hanneken JM, Taylor S, Liu S, Lee JJ, Stewart DJ, Wistuba II, Lippman SM, Karp DD. Importance of tumor location and histology in long term survivors (LTS) of non small cell lung cancer (NSCLC) treated without surgery. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 17524. PMID 27950473 DOI: 10.1200/jco.2008.26.15_suppl.17524 |
0.14 |
|
| 2007 |
Oh Y, Lee JJ, Hanneken JM, Liu S, Camarillo MC, Taylor SH, Lippman SM, Hong WK, Stewart DJ, Karp DD. New perspectives on metastatic patterns in lung cancer: The M. D. Anderson thoracic medical oncology database Journal of Clinical Oncology. 25: 7630-7630. DOI: 10.1200/JCO.2007.25.18_SUPPL.7630 |
0.138 |
|
| 2017 |
Guo B, Liu S. Optimal Benchmark for Evaluating Drug-Combination Dose-Finding Clinical Trials Statistics in Biosciences. 10: 184-201. DOI: 10.1007/S12561-017-9204-1 |
0.137 |
|
| 2007 |
Karp DD, Hanneken JM, Taylor SH, Liu S, Johnson ED, Wistuba II, Swisher SG, Munden R, Stewart DJ. P2-188: Upper lobe lesions dominate in patients with long term survival of non-surgically treated non small cell lung cancer Journal of Thoracic Oncology. 2: S644-S645. DOI: 10.1097/01.JTO.0000283846.61525.5F |
0.134 |
|
| 2021 |
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, et al. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discovery. PMID 34261675 DOI: 10.1158/2159-8290.CD-21-0331 |
0.133 |
|
| 2020 |
Yan F, Zhang L, Zhou Y, Pan H, Liu S, Yuan Y. BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs Journal of Statistical Software. 94. DOI: 10.18637/jss.v094.i13 |
0.133 |
|
| 2020 |
Pezzi T, Fang P, Gjyshi O, Feng L, Liu S, Komaki R, Lin S. The Role of Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer in the MRI Era International Journal of Radiation Oncology*Biology*Physics. 108: e85. DOI: 10.1016/J.IJROBP.2020.07.1178 |
0.132 |
|
| 2022 |
Lu M, Liu S, Yuan Y. Why there are so many contradicted or exaggerated findings in highly-cited clinical research? Contemporary Clinical Trials. 118: 106782. PMID 35525531 DOI: 10.1016/j.cct.2022.106782 |
0.129 |
|
| 2011 |
Rathi N, Dinh A, Haque SA, Feng L, Liu S, Dong W, Nates JL, Price KJ, Popat U. Outcomes of High Dose Steroid Treatment with or without Aminocaproic Acid in Critically Ill Stem Cell Transplant Recipients with Diffuse Alveolar Hemorrhage Blood. 118: 3058-3058. DOI: 10.1182/BLOOD.V118.21.3058.3058 |
0.125 |
|
| 2021 |
Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. Jama Network Open. 4: e2119934. PMID 34357397 DOI: 10.1001/jamanetworkopen.2021.19934 |
0.124 |
|
| 2019 |
Manzano JG, Park A, Lin H, Liu S, Halm J. Demonstrating value: association of cost and quality outcomes with implementation of a value-driven oncology-hospitalist inpatient collaboration for patients with lung cancer. Bmj Open Quality. 8: e000381. PMID 30997414 DOI: 10.1136/bmjoq-2018-000381 |
0.121 |
|
| 2013 |
Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 69: 914-24. PMID 24328715 DOI: 10.1111/Biom.12100 |
0.121 |
|
| 2007 |
Johnson ED, Hanneken JM, Liu S, Rojo J, Taylor SH, Stewart DJ, Camarillo MC, Wistuba II, Lippman SM, Karp DD. P2-186: The incidence of histologic subtypes and b symptoms in long term survival of non surgically treated non small cell lung cancer Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283844.53901.Be |
0.118 |
|
| 2022 |
Qiao W, Young E, Feng C, Liu S, Jin J, Noor L, Rojas Hernandez CM, Borthakur G, Gorlova O, Afshar-Kharghan V. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. Experimental Hematology & Oncology. 11: 58. PMID 36114519 DOI: 10.1186/s40164-022-00309-7 |
0.112 |
|
| 2022 |
Le UQ, Chen N, Balasenthil S, Lurie E, Yang F, Liu S, Rubin L, Solis Soto LM, Raso MG, Batra H, Sahin AA, Wistuba II, Killary AM. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Scientific Reports. 12: 19504. PMID 36376460 DOI: 10.1038/s41598-022-22417-4 |
0.111 |
|
| 2021 |
Gjyshi O, Lin SH, Pezzi TA, Ning MS, Ma J, Liu S, Rusthoven CG. Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clinical Lung Cancer. PMID 34419375 DOI: 10.1016/j.cllc.2021.07.003 |
0.106 |
|
| 2024 |
Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, ... ... Liu S, et al. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Science Signaling. 17: eadh4475. PMID 38442201 DOI: 10.1126/scisignal.adh4475 |
0.104 |
|
| 2017 |
Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute. 109. PMID 28376184 DOI: 10.1093/Jnci/Djw341 |
0.1 |
|
| 2007 |
Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Molecular Cancer Therapeutics. 6: 1962-72. PMID 17620427 DOI: 10.1158/1535-7163.Mct-07-0052 |
0.1 |
|
| 2005 |
Consens FB, Chervin RD, Koeppe RA, Little R, Liu S, Junck L, Angell K, Heumann M, Gilman S. Validation of a polysomnographic score for REM sleep behavior disorder. Sleep. 28: 993-7. PMID 16218083 DOI: 10.1093/Sleep/28.8.993 |
0.097 |
|
| 2017 |
Lu H, Murphy WA, Ebede CC, Karim E, Rondon G, Leung CH, Liu S, Champlin RE, Pundole X. Exploration of risk factors for osteoporotic fracture following hematopoietic stem cell transplantation. Journal of Clinical Oncology. 35: 10080-10080. DOI: 10.1200/JCO.2017.35.15_SUPPL.10080 |
0.096 |
|
| 2019 |
Shen W, Liu S, Chen Y, Ning J. Regression analysis of longitudinal data with outcome-dependent sampling and informative censoring. Scandinavian Journal of Statistics, Theory and Applications. 46: 831-847. PMID 32066989 DOI: 10.1111/Sjos.12373 |
0.096 |
|
| 2022 |
Mechref Y, Peng W, Gautam S, Ahmadi P, Lin Y, Zhu J, Zhang J, Liu S, Singal AG, Parikh ND, Lubman DM. Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach. Advances in Cancer Research. 157: 23-56. PMID 36725111 DOI: 10.1016/bs.acr.2022.07.005 |
0.095 |
|
| 2021 |
Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S. Plasma MicroRNA Biomarkers in Limited Volume Samples for Detection of Early Stage Pancreatic Cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 33893071 DOI: 10.1158/1940-6207.CAPR-20-0303 |
0.092 |
|
| 2020 |
Liu S. Higher education and Sustainable Development Goals during COVID-19: coping strategies of a university in Wuhan, China. Journal of Public Health Research. 9: 1933. PMID 33409250 DOI: 10.4081/jphr.2020.1933 |
0.09 |
|
| 2011 |
Rathi N, Dinh A, Haque S, Feng L, Liu S, Dong W, Hovden M, Price K, Nates J. Aminocaproic Acid Does Not Reduce Mortality in Cancer Patients With Diffuse Alveolar Hemorrhag Chest. 140: 203A. DOI: 10.1378/CHEST.1118432 |
0.089 |
|
| 2021 |
Gutierrez Reyes CD, Huang Y, Atashi M, Zhang J, Zhu J, Liu S, Parikh ND, Singal AG, Dai J, Lubman DM, Mechref Y. PRM-MS Quantitative Analysis of Isomeric -Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma. Metabolites. 11. PMID 34436504 DOI: 10.3390/metabo11080563 |
0.086 |
|
| 2022 |
Lin Y, Zhu J, Zhang J, Dai J, Liu S, Arroyo A, Rose M, Singal AG, Parikh ND, Lubman DM. Glycopeptides with Sialyl Lewis Antigen in Serum Haptoglobin as Candidate Biomarkers for Nonalcoholic Steatohepatitis Hepatocellular Carcinoma Using a Higher-Energy Collision-Induced Dissociation Parallel Reaction Monitoring-Mass Spectrometry Method. Acs Omega. 7: 22850-22860. PMID 35811936 DOI: 10.1021/acsomega.2c02600 |
0.085 |
|
| 2017 |
Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. Bmj Supportive & Palliative Care. PMID 28860112 DOI: 10.1136/bmjspcare-2017-001388 |
0.083 |
|
| 2022 |
Liu S, Ding W. Chinese universities' special programs supporting talents to seek a United Nations career: a center-periphery-model analysis. Higher Education. 1-20. PMID 36268463 DOI: 10.1007/s10734-022-00938-1 |
0.082 |
|
| 2017 |
Kadjo AF, Dasgupta PK, Su J, Liu S, Kraiczek KG. Width Based Quantitation of Chromatographic Peaks. Principles and Principal Characteristics. Analytical Chemistry. PMID 28244311 DOI: 10.1021/Acs.Analchem.6B04857 |
0.082 |
|
| 2020 |
Zhu J, Huang J, Zhang J, Chen Z, Lin Y, Grigorean G, Li L, Liu S, Singal AG, Parikh ND, Lubman DM. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Non-Alcoholic Steatohepatitis. Journal of Proteome Research. PMID 32412768 DOI: 10.1021/Acs.Jproteome.0C00270 |
0.082 |
|
| 2018 |
Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. Bmc Medical Research Methodology. 18: 32. PMID 29580203 DOI: 10.1186/S12874-018-0473-2 |
0.081 |
|
| 2022 |
Ding F, Zhang S, Liu S, Feng J, Li J, Li Q, Ge Z, Zuo X, Fan C, Xia Q. Molecular Visualization of Early-Stage Acute Kidney Injury with a DNA Framework Nanodevice. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2105947. PMID 35508712 DOI: 10.1002/advs.202105947 |
0.076 |
|
| 2018 |
Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu H. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Archives of Osteoporosis. 13: 38. PMID 29619576 DOI: 10.1007/S11657-018-0453-5 |
0.073 |
|
| 2009 |
Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5359-68. PMID 19706809 DOI: 10.1158/1078-0432.CCR-09-0033 |
0.072 |
|
| 2019 |
Liang J, Zhu J, Wang M, Singal AG, Odewole M, Kagan S, Renteria V, Liu S, Parikh ND, Lubman DM. Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. Scientific Reports. 9: 11580. PMID 31399619 DOI: 10.1038/S41598-019-48043-1 |
0.072 |
|
| 2020 |
Cabanillas ME, Dadu R, Ferrarotto R, Liu S, Fellman BM, Gross ND, Gule-Monroe M, Lu C, Grosu H, Williams MD, Duose DY, Mallampati S, Dervin S, Mckenna EF, Wang RJ, et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). Journal of Clinical Oncology. 38: 6514-6514. DOI: 10.1200/Jco.2020.38.15_Suppl.6514 |
0.071 |
|
| 2011 |
Momoh AO, Yu P, Skoracki RJ, Liu S, Feng L, Hanasono MM. A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plastic and Reconstructive Surgery. 128: 714-20. PMID 21572380 DOI: 10.1097/PRS.0b013e318221dc2a |
0.068 |
|
| 2022 |
Liu S. International Organizations' Policy Response to COVID-19 in Longer Terms. Global Policy. PMID 35602415 DOI: 10.1111/1758-5899.13087 |
0.067 |
|
| 2022 |
Lv S, Wang J, You R, Liu S, Ding Y, Hadianamrei R, Tomeh MA, Pan F, Cai Z, Zhao X. Highly selective performance of rationally designed antimicrobial peptides based on ponericin-W1. Biomaterials Science. PMID 35861280 DOI: 10.1039/d2bm00744d |
0.066 |
|
| 2014 |
Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics. 70: 366-77. PMID 24575781 DOI: 10.1111/Biom.12146 |
0.065 |
|
| 2011 |
Savar A, Esmaeli B, Ho H, Liu S, Prieto VG. Conjunctival melanoma: local-regional control rates, and impact of high-risk histopathologic features. Journal of Cutaneous Pathology. 38: 18-24. PMID 20860727 DOI: 10.1111/j.1600-0560.2010.01625.x |
0.063 |
|
| 2023 |
Xu R, Tang J, Hadianamrei R, Liu S, Lv S, You R, Pan F, Zhang P, Wang N, Cai Z, Zhao X. Antifungal activity of designed α-helical antimicrobial peptides. Biomaterials Science. PMID 36857655 DOI: 10.1039/d2bm01797k |
0.058 |
|
| 2013 |
Hao L, Jiang G, Liu S, Ling L. Global dynamics of an SIRS epidemic model with saturation incidence. Bio Systems. 114: 56-63. PMID 23891842 DOI: 10.1016/j.biosystems.2013.07.009 |
0.056 |
|
| 2016 |
Liu S, Wang Q, Fan D. Disinhibition-Induced Delayed Onset of Epileptic Spike-Wave Discharges in a Five Variable Model of Cortex and Thalamus. Frontiers in Computational Neuroscience. 10: 28. PMID 27092070 DOI: 10.3389/fncom.2016.00028 |
0.056 |
|
| 2014 |
Liu S, Perra N, Karsai M, Vespignani A. Controlling contagion processes in activity driven networks Physical Review Letters. 112. PMID 24702426 DOI: 10.1103/Physrevlett.112.118702 |
0.055 |
|
| 2016 |
Fan D, Liu S, Wang Q. Stimulus-induced Epileptic Spike-Wave Discharges in Thalamocortical Model with Disinhibition. Scientific Reports. 6: 37703. PMID 27876879 DOI: 10.1038/srep37703 |
0.047 |
|
| 2023 |
Balasenthil S, Liu S, Dai J, Bamlet WR, Petersen G, Chari ST, Maitra A, Chen N, Sen S, McNeill Killary A. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes. Clinica Chimica Acta; International Journal of Clinical Chemistry. 551: 117567. PMID 37774897 DOI: 10.1016/j.cca.2023.117567 |
0.045 |
|
| 2005 |
Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 936-44. PMID 15937303 |
0.044 |
|
| 2022 |
Liao W, Liu S, Chen Y, Kong Y, Wang D, Wang Y, Ling T, Xie Z, Khalilova I, Huang J. Effects of Keemun and Dianhong Black Tea in Alleviating Excess Lipid Accumulation in the Liver of Obese Mice: A Comparative Study. Frontiers in Nutrition. 9: 849582. PMID 35369079 DOI: 10.3389/fnut.2022.849582 |
0.042 |
|
| 2008 |
Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, Lee JH, Couriel D. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. The American Journal of Gastroenterology. 103: 982-9. PMID 18028511 DOI: 10.1111/j.1572-0241.2007.01639.x |
0.04 |
|
| 2006 |
Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, Heumann M, Gilman S. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 1769-77. PMID 17079809 |
0.04 |
|
| 2010 |
Gao B, Liu S, Li Y. Preparation and recognition performance of uric acid-imprinted material prepared with novel surface imprinting technique. Journal of Chromatography. A. 1217: 2226-36. PMID 20226467 DOI: 10.1016/j.chroma.2010.02.027 |
0.039 |
|
| 2020 |
Sun W, Li Y, Liu S. Noisy consensus dynamics in windmill-type graphs. Chaos (Woodbury, N.Y.). 30: 123131. PMID 33380064 DOI: 10.1063/5.0020696 |
0.032 |
|
| Hide low-probability matches. |